Maximizing the Therapeutic Potential of Janus Kinase 2 (JAK2) Inhibitors in Patients with Chronic Myelofibrosis

http://academiccme.com/wp-content/uploads/2015/06/27_Website-Graphic.png

Course Information

Therapautic Area: Hematology
Format(s): Webcast
Credit(s): N/A
Activity Dates: April 2, 2014 - April 1, 2015

 

This course is still available as a learning tool but has expired for CME credit.

Program Overview

The pathobiology of myelofibrosis continues to advance and the current understanding of myelofibrosis is complex. Guidelines and recommendations for the diagnosis of myelofibrosis, including the revised WHO criteria for myelofibrosis, is controversial. The clinical trial data on JAK2 inhibitor therapeutics has changed the clinical approach to patients with this illness. The expert faculty will emphasize the issues around the application of JAK2 inhibitors for the treatment of myelofibrosis in clinical practice.

The format of this CME webcast combines the presentation of current science with interactive expert panel analysis and learner participation. This allows for a deeper insight into the data and the bench-to-bedside process.

Target Audience

Hematologists-oncologists, oncologists, and other clinicians involved in the management and treatment of patients with myelofibrosis.

Learning Objectives

  1. Discuss recent advances in obesity science and the development of novel therapies
  2. Apply the most up-to-date safety and efficacy data for currently available and emerging therapies for the management of patients with obesity.
  3. Create individualized treatment plans and appropriate weight management strategies to improve patient outcomes

Registration



This activity has been supported by an independent educational grant from sanofi-aventis U.S. LLC.

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME

eocme acme logo